Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Bassil, AK"'
Autor:
Bassil, AK1, Taylor, CM2, Bolton, VJN1, Gray, KM1, Brown, JD2, Cutler, L1, Summerfield, SG3, Bruton, G1, Winchester, WJ1, Lee, K1, Sanger, GJ1, Bassil, A K4 (AUTHOR), Taylor, C M (AUTHOR), Bolton, V J N (AUTHOR), Gray, K M (AUTHOR), Brown, J D (AUTHOR), Summerfield, S G (AUTHOR), Winchester, W J (AUTHOR), Sanger, G J (AUTHOR)
Publikováno v:
British Journal of Pharmacology. Sep2009, Vol. 158 Issue 1, p252-258. 7p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Furze RC; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Molnar J; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.; Galapagos, Cambridge, UK., Parr NJ; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.; MoonFire Consultancy Ltd, Hertfordshire, UK., Ahmad F; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.; Galderma R&D, Fort Worth, TX, USA., Henry Y; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.; YMH-Management Ltd, Lancashire, UK., Howe D; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.; SoseiHeptares, Cambridge, UK., Singh R; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.; GlaxoSmithKline, Collegeville, PA, USA., Toal M; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.; Conan Biopharma Consulting, Wokingham, UK., Bassil AK; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Bernard SG; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Davis RP; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Gibson A; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Maller NC; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Sharp C; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Tough DF; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Prinjha RK; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Lewis HD; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.
Publikováno v:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 Dec; Vol. 88 (12), pp. 5238-5256. Date of Electronic Publication: 2022 Jul 11.
Autor:
Gilan O; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Rioja I; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Knezevic K; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Bell MJ; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Yeung MM; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Harker NR; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Lam EYN; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Chung CW; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Bamborough P; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Petretich M; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Urh M; Promega Corporation, Madison, WI, USA., Atkinson SJ; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Bassil AK; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Roberts EJ; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Vassiliadis D; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Burr ML; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Preston AGS; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Wellaway C; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Werner T; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Gray JR; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Michon AM; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Gobbetti T; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Kumar V; Computational Biology, GlaxoSmithKline, Collegeville, PA, USA., Soden PE; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Haynes A; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Vappiani J; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Tough DF; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Taylor S; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Dawson SJ; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia., Bantscheff M; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Lindon M; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Drewes G; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Demont EH; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Daniels DL; Promega Corporation, Madison, WI, USA., Grandi P; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Prinjha RK; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK. mark.dawson@petermac.org rabinder.prinjha@gsk.com., Dawson MA; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. mark.dawson@petermac.org rabinder.prinjha@gsk.com.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia.
Publikováno v:
Science (New York, N.Y.) [Science] 2020 Apr 24; Vol. 368 (6489), pp. 387-394. Date of Electronic Publication: 2020 Mar 19.
Autor:
Dobenecker MW; Laboratory of Immune Cell Epigenetics and Signaling, The Rockefeller University, New York, NY dobenem@rockefeller.edu., Park JS; Laboratory of Immune Cell Epigenetics and Signaling, The Rockefeller University, New York, NY., Marcello J; Laboratory of Immune Cell Epigenetics and Signaling, The Rockefeller University, New York, NY.; Now, Faculty of Biology, University of Freiburg, Freiburg, Germany., McCabe MT; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA., Gregory R; Epigenetics Discovery Performance Unit, Immuno-Inflammation TA, Medicines Research Centre, GlaxoSmithKline Research and Development, Stevenage, England, UK., Knight SD; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA., Rioja I; Epigenetics Discovery Performance Unit, Immuno-Inflammation TA, Medicines Research Centre, GlaxoSmithKline Research and Development, Stevenage, England, UK., Bassil AK; Epigenetics Discovery Performance Unit, Immuno-Inflammation TA, Medicines Research Centre, GlaxoSmithKline Research and Development, Stevenage, England, UK., Prinjha RK; Epigenetics Discovery Performance Unit, Immuno-Inflammation TA, Medicines Research Centre, GlaxoSmithKline Research and Development, Stevenage, England, UK., Tarakhovsky A; Laboratory of Immune Cell Epigenetics and Signaling, The Rockefeller University, New York, NY tarakho@rockefeller.edu.
Publikováno v:
The Journal of experimental medicine [J Exp Med] 2018 Apr 02; Vol. 215 (4), pp. 1101-1113. Date of Electronic Publication: 2018 Mar 09.
Autor:
Chaidos A; Centre for Haematology, Department of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom;, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, Rotolo A, Tough DF, Smithers NN, Bassil AK, Chapman TD, Harker NR, Barbash O, Tummino P, Al-Mahdi N, Haynes AC, Cutler L, Le B, Rahemtulla A, Roberts I, Kleijnen M, Witherington JJ, Parr NJ, Prinjha RK, Karadimitris A
Publikováno v:
Blood [Blood] 2014 Jan 30; Vol. 123 (5), pp. 697-705. Date of Electronic Publication: 2013 Dec 13.
UDP-glucose modulates gastric function through P2Y14 receptor-dependent and -independent mechanisms.
Autor:
Bassil AK; Department of Gastrointestinal Research, Neurology and Gastrointestinal Centre of Excellence for Drug Discovery, Harlow, UK., Bourdu S, Townson KA, Wheeldon A, Jarvie EM, Zebda N, Abuin A, Grau E, Livi GP, Punter L, Latcham J, Grimes AM, Hurp DP, Downham KM, Sanger GJ, Winchester WJ, Morrison AD, Moore GB
Publikováno v:
American journal of physiology. Gastrointestinal and liver physiology [Am J Physiol Gastrointest Liver Physiol] 2009 Apr; Vol. 296 (4), pp. G923-30. Date of Electronic Publication: 2009 Jan 22.